Summary News Back
Rising awareness and media coverage of liver diseases, particularly PBC, including expert discussions and patient stories on various platforms.
Promising clinical trial results for new PBC treatments such as linerixibat, seladelpar (Livdelzi), and elafibranor (Iqirvo), showing improvements in symptoms like itch and fatigue.
Regulatory progress with multiple approvals and conditional authorizations of PBC treatments across Europe, the US, and the UK (e.g., Livdelzi, Iqirvo).
Ongoing research into the mechanisms and associated conditions of PBC, including links to lymphoma, systemic sclerosis, and gut microbiota.
Growing investment and milestone payments in the PBC drug development sector, reflecting commercial interest and expanding treatment options.
Studies highlighting the importance of early diagnosis, personalized treatment plans, and quality of life improvements for PBC patients.
Concerns over safety and effectiveness of existing treatments, with regulatory bodies declining or revoking approvals (e.g., Ocaliva).
Educational efforts through art, patient stories, and physician guidance to support awareness and understanding of rare liver diseases like PBC.
News Articles Back
21/11/2025 Patients with Primary Biliary Cholangitis Miss Recommended Monitoring - European Medical Journal
21/11/2025 Systemic PCSK9 elevation characterises autoimmune liver disease across sexes - Nature
19/11/2025 Blood group A linked to a higher risk of primary biliary cholangitis - News-Medical
18/11/2025 Primary Biliary Cholangitis (PBC) Treatment Market to Reach USD 2.72 Billion by 2033, Driven by Next-Generation FXR Agonists & Immunomodulators | DataM Intelligence - PR Newswire
18/11/2025 Future of the Global Primary Biliary Cholangitis Market: Trends, Innovations, and Key Forecasts Through 2034 - openPR.com
10/11/2025 Seladelpar Staves Off Liver Stiffness in PBC - Medscape
07/11/2025 Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression - Yahoo Finance
06/11/2025 Seladelpar Reduces Itching in Primary Biliary Cholangitis - Medscape
05/11/2025 VIDEO: Scoring tools may help identify nonresponders in primary biliary cholangitis - Healio
30/10/2025 Seladelpar’s Impact on Pruritus in Primary Biliary Cholangitis, With Marlyn Mayo, MD - HCPLive
30/10/2025 Ipsen at The Liver Meeting 2025 - Ipsen
29/10/2025 Research Communication: Real-World Clinical Experience With Seladelpar in Primary Biliary Cholangitis - Wiley Online Library
27/10/2025 Exploring primary biliary cholangitis - Healio
23/10/2025 (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - Business Wire
21/10/2025 LYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS - PR Newswire Canada
14/10/2025 Multi-omics tests identify novel shared genetic mechanisms of primary biliary cholestasis and sarcopenia - Nature
10/10/2025 Bezafibrate for primary biliary cholangitis: time to act on the evidence - Nature
07/10/2025 Linerixibat Reduces Itching in PBC - Medscape
03/10/2025 Primary Biliary Cholangitis (PBC) Workup: Approach Considerations, Laboratory Studies, Imaging Studies - Medscape eMedicine
01/10/2025 PBC worst for life quality among autoimmune liver diseases: Study - Liver Disease News
19/09/2025 Mixed Multiple Autoimmune Syndrome Type 3 With Coexistence of Primary Biliary Cholangitis, Inflammatory Myopathy, and Chronic Thyroiditis: A Case Report - Cureus
15/09/2025 Common pathological mechanisms and therapeutic strategies in primary Sjogren’s syndrome and primary biliary cholangitis: from tissue immune microenvironment to targeted therapy - Frontiers
12/09/2025 Liver Disease Drug Pulled From the Market - MedPage Today
11/09/2025 Ocaliva for PBC Withdrawn From US Market - Medscape
11/09/2025 Intercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold - Yahoo Finance
10/09/2025 Gilead fashions new primary biliary cholangitis campaign alongside 'Project Runway' designer - Fierce Pharma
10/09/2025 September's PBC Awareness Month raises support for a rare liver... - Liver Disease News
10/09/2025 DESIGNER MONDO GUERRA DEBUTS FASHION COLLECTION INSPIRED BY THE EMOTIONAL REALITIES OF PEOPLE LIVING WITH PBC - MultiVu
05/09/2025 Innate immunity of bile and cholangiocytes in primary biliary cholangitis - Frontiers
01/09/2025 Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis - BioSpace
29/08/2025 Zydus Therapeutics announces positive topline results from EPICS-III Phase 2b/3 trial of Saroglitazar in Primary Biliary Cholangitis - Express Pharma
27/08/2025 Local Woman Launches Support Group For People With Primary Biliary Cholangitis - The Citizen Newspaper Group
25/08/2025 Understanding PBC: Managing what Matters Most - Ipsen
18/08/2025 Primary Sclerosing Cholangitis (PSC) Market | Global Market Analysis Report - 2035 - Future Market Insights
11/08/2025 IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight - Yahoo Finance
09/08/2025 Early assessment of treatment response in primary biliary cholangitis: key to timely management - BMC Gastroenterology
03/08/2025 Research progress and perspectives of non-coding RNAs in primary biliary cholangitis: from mechanisms to therapeutics - Frontiers
23/07/2025 PPAR agonists effective in UDCA-resistant primary biliary cholangitis - Liver Disease News
18/07/2025 The effectiveness of combining ursodeoxycholic acid with vitamin D in treating patients with primary biliary cholangitis and its impact on hepatic fibrosis: a randomized trial - BMC Gastroenterology
17/07/2025 GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights - Yahoo Finance
08/07/2025 Fulminant Primary Biliary Cholangitis-Autoimmune Hepatitis (PBC-AIH) Overlap Syndrome in a 27-Year-Old Woman With Childhood-Onset AIH: Steroid-Refractory Decompensation Necessitating Urgent Transplant Evaluation - Cureus
02/07/2025 Endothelial cells expressing CPE and vWF are involved in the Immunopathogenesis of primary biliary cholangitis - Nature
02/07/2025 Nearly half of PBC patients in US haven’t seen a specialist recently - Liver Disease News
02/07/2025 Hepatic Encephalopathy Induced by Small Bowel Obstruction in a Patient With Primary Biliary Cholangitis - Cureus
30/06/2025 Treatment of pruritus in primary biliary cholangitis - Clínica FEHV
20/06/2025 Novel Therapies for Primary Biliary Cholangitis - Medscape Reference
11/06/2025 T and B cell responses against Epstein–Barr virus in primary sclerosing cholangitis - Nature
04/06/2025 FDA Accepts GSKs NDA for First-in-Class IBAT Inhibitor Linerixibat to Treat Cholestatic Pruritus in Primary Biliary Cholangitis - PharmExec.com
02/06/2025 Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC) - GSK
22/05/2025 New Kids on the Block: Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis - European Medical Journal
20/05/2025 Elafibranor Seladelpar Efficacy Liver Meeting - Gastroenterology & Endoscopy News
20/05/2025 Linerixibat Significantly Improves PBC-Related Cholestatic Pruritus in Adult Patients - Pharmacy Times
19/05/2025 Double Trouble: Drug-Induced Autoimmune Hepatitis (AIH)-Primary Biliary Cholangitis (PBC) Overlap Syndrome Triggered by Hydralazine - Cureus
15/05/2025 Seladelpar Safe Effective Primary Biliary Cholangitis Cirrhosis PBC - Gastroenterology & Endoscopy News
14/05/2025 Livdelzi effective on primary biliary cholangitis, regardless of prior treatment - Liver Disease News
12/05/2025 Drug Slows Progression of Primary Sclerosing Cholangitis - Medscape
09/05/2025 Gilead’s Livdelzi Shows Lasting Efficacy in Primary Biliary Cholangitis, Regardless of Prior Therapy - PharmExec.com
09/05/2025 Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL - Business Wire
08/05/2025 Iqirvo Shows Significant Fatigue Improvement in Patients with Primary Biliary Cholangitis After 52 Weeks in Phase III ELATIVE Trial - Applied Clinical Trials
08/05/2025 Oral IBAT Inhibitor Improves Cholestatic Itch in Primary Biliary Cholangitis - MedPage Today
08/05/2025 Sleep Disorders and PBC Disease Severity, with Ana Marenco Flores, MD - HCPLive
07/05/2025 Bringing PBC Into Focus Through Art of Patient Stories - Gilead Sciences
06/05/2025 Ipsen to present new data across four rare liver diseases at EASL, including late-breaking data in PBC and PSC - Ipsen
02/05/2025 Gilead and Advocacy Groups Partner with Artist and Filmmaker to Illuminate the Hidden Realities of Living with PBC - MultiVu
28/04/2025 Health Canada approves IQIRVO® as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis - Ipsen
25/04/2025 Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis - PMLiVE
23/04/2025 90% of People With This Rare Liver Disease Are Women—Meet the Patient Advocate Helping Empower Others - Flow Space
14/04/2025 Bibliometric analysis of research on intestinal flora and primary biliary cholangitis published between 2004 and 2024 using VOSviewer and CiteSpace visualization - Frontiers
10/04/2025 Systemic Sclerosis and Primary Biliary Cholangitis: A Comprehensive Review of Two Overlapping Rare Entities With Insights on Diagnostics and Management - Cureus
08/04/2025 Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis - PMLiVE
07/04/2025 The Scottish Medicines Consortium (SMC) accepts Ipsen’s IQIRVO® (elafibranor) for use in NHS Scotland – the first new medicine in nearly a decade for primary biliary cholangitis (PBC), a rare liver disease - Ipsen
07/04/2025 New vision for rare liver condition - HealthandCare.scot
26/03/2025 2nd-line PBC treatment options call for personalized care: Analysis - Liver Disease News
26/03/2025 Living with Rare Liver Diseases: Unique challenges, Shared Experiences - Ipsen
21/03/2025 The Evolving Primary Biliary Cholangitis Landscape, with Craig Lammert, MD - HCPLive
11/03/2025 Cirrhotic PBC Linked to High Comorbidity Burden, Healthcare Resource Utilization - HCPLive
07/03/2025 Autoimmune Gastritis Complicated by Primary Biliary Cholangitis: A Report of Two Cases and Literature Review - Cureus
07/03/2025 A Rare Case of Concurrent Primary Biliary Cholangitis and Sarcoidosis - Cureus
26/02/2025 Seladelpar approved to help treat primary biliary cholangitis in EU - Liver Disease News
26/02/2025 Guidelines on the diagnosis and management of primary biliary cholangitis - EurekAlert!
24/02/2025 Breaking Grounds: A Comprehensive Analysis of Cutting-Edge Treatments for Primary Biliary Cirrhosis/Primary Biliary Cholangitis With Futuristic Treatments - Cureus
23/02/2025 Coexisting Primary Biliary Cholangitis and Diffuse Large B-Cell Lymphoma: A Case Report and Literature Review - Cureus
21/02/2025 Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis - BioSpace
20/02/2025 EU okays Gilead's seladelpar for primary biliary cholangitis - FirstWord Pharma
17/02/2025 Primary Biliary Cholangitis in a Patient With Multiple Sclerosis: A Case Report - Cureus
13/02/2025 Elafibranor Increase Survival Primary Biliary Cholangitis Patients PBC - Gastroenterology & Endoscopy News
22/01/2025 Livdelzi approved in UK as PBC treatment for certain adults - Liver Disease News
20/01/2025 New treatment for primary biliary cholangitis - Clínica FEHV
20/01/2025 Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults - PMLiVE
10/01/2025 Exploration of Novel Metabolic Mechanisms Underlying Primary Biliary Cholangitis Using Hepatic Metabolomics, Lipidomics, and Proteomics Analysis - ACS Publications
10/01/2025 FDA Grants Orphan Drug Designation to CNP-104 for Primary Biliary Cholangitis - Pharmacy Times
08/01/2025 FDA Grants Orphan Drug Designation to CNP-104 for Primary Biliary Cholangitis - HCPLive
08/01/2025 Cour Pharmaceuticals snags orphan drug designation for CNP-104 for the treatment of PBC - Healio
08/01/2025 COUR Pharmaceuticals Secures FDA Orphan Drug Designation for CNP-104 in Primary Biliary Cholangitis - GlobeNewswire
06/01/2025 A Rare Case of Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome in a Male Patient - Cureus
02/01/2025 Serious liver injury being observed in patients without cirrhosis taki - fda.gov
28/12/2024 Development and external validation of an early prediction model to identify irresponsive patients and prognosis of UDCA treatment in primary biliary cholangitis - Nature
23/12/2024 Prompt Diagnosis, Management of Primary Biliary Cholangitis Key to Quality of Life - MedPage Today
13/12/2024 EMA Recommends Seladelpar for Primary Biliary Cholangitis - Medscape
11/12/2024 Sleep disorders common in PBC, linked to severe disease: Study - Liver Disease News
